Molecular characteristics of gastric cancer with ERBB2 amplification

Molecular characteristics of gastric cancer with ERBB2 amplification

Gastric cancer is a prevalent malignancy with a high degree of heterogeneity, which has led to a poor therapeutic response. Though there are numerous HER2-targeted medicines for HER2+ gastric cancer, many trials have not indicated an improvement in overall survival. Here 29 ERBB2 amplification (ERBB...

Full description

Bibliographic Details
Main Authors:	Dongyan Cao, Hongping Xu, Longteng Li, Zheng Ju, Baiqiang Zhai
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Heliyon
Subjects:	Gastric cancer ERBB2 HER2 WGCNA EMT
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023058620

Similar Items

The ERBB2 gene polymorphisms rs2643194, rs2934971, and rs1058808 are associated with increased risk of gastric cancer
by: K.C. Vázquez-Ibarra, et al.
Published: (2019-05-01)

Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance
by: Cheng Guoxiong, et al.
Published: (2019-05-01)

Cardiac Melanoma Metastasis with ERBB2 Gene Amplification: A Potential for Future Targeted Therapy
by: Polona Gams, et al.
Published: (2021-03-01)

Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01)

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies
by: Nannan Wang, et al.
Published: (2022-10-01)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
by: Jeeyun Lee, et al.
Published: (2019-04-01)

Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors
by: Yin Guan, et al.
Published: (2022-10-01)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
by: Javier Torres-Jiménez, et al.
Published: (2022-07-01)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
by: Fatih M. Uckun, et al.
Published: (2023-06-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients
by: Yanhong Shang, et al.
Published: (2023-01-01)

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors
by: Hao Wang, et al.
Published: (2022-07-01)

ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition
by: Afsaneh Barzi, et al.
Published: (2024-02-01)

Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
by: Wen Jian, et al.
Published: (2020-03-01)

NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells
by: Carmen Miano, et al.
Published: (2022-03-01)

Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant
by: Lu Yang, et al.
Published: (2015-05-01)

Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies
by: Carmen Miano, et al.
Published: (2022-05-01)

The role of autophagy in HER2-targeted therapy
by: Félice A. Janser, et al.
Published: (2019-10-01)

GPAA1 promotes gastric cancer progression via upregulation of GPI-anchored protein and enhancement of ERBB signalling pathway
by: Xiao-Xin Zhang, et al.
Published: (2019-05-01)

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
by: Ioannis A. Vathiotis, et al.
Published: (2021-12-01)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
by: Ilianna Zoi, et al.
Published: (2019-12-01)

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
by: Leonie D. H. Gossel, et al.
Published: (2021-03-01)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
by: Shuo Wang, et al.
Published: (2022-04-01)

ERBB2‐amplified lobular breast carcinoma exhibits concomitant CDK12 co‐amplification associated with poor prognostic features
by: Miriam Forster‐Sack, et al.
Published: (2024-03-01)

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
by: Arik Durcker, et al.
Published: (2020-10-01)

Activating mutations in ERBB2 and their impact on diagnostics and treatment
by: Grit Sophie Herter-Sprie, et al.
Published: (2013-04-01)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
by: Catrin Heim, et al.
Published: (2023-08-01)

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies
by: Cheng Zhang, et al.
Published: (2020-12-01)

Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer
by: Soojung Lee, et al.
Published: (2023-04-01)

HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
by: Babak Nami, et al.
Published: (2017-04-01)

Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models
by: Chidiebere U. Awah, et al.
Published: (2023-06-01)

The Mysterious Ways of ErbB2/HER2 Trafficking
by: Vibeke Bertelsen, et al.
Published: (2014-08-01)

The Genomic Landscape of Urothelial Carcinoma with High and Low <i>ERBB2</i> Expression
by: Agreen Hadadi, et al.
Published: (2023-12-01)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
by: Alexander J. Neil, et al.
Published: (2023-08-01)

Time to Deliver on Promises: The Role of ERBB2 Alterations as Treatment Options for Colorectal Cancer Patients in the Era of Precision Oncology
by: Soeren M. Buchholz, et al.
Published: (2023-12-01)

Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells
by: Yongqiang Chen, et al.
Published: (2021-03-01)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021-08-01)

Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
by: Kathrin Hedegger, et al.
Published: (2020-08-01)

ELAC2 Functions as a Key Gene in the Early Development of Placental Formation Based on WGCNA
by: Junyong Liang, et al.
Published: (2023-02-01)

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
by: Snježana Mikuličić, et al.
Published: (2024-02-01)